The Growing Importance of Local Literature Monitoring in Pharmacovigilance
Pharmacovigilance has evolved far beyond collecting spontaneous adverse event reports. Today, regulatory authorities expect Marketing Authorization Holders (MAHs) to proactively monitor scientific literature throughout a product's lifecycle to identify emerging safety concerns as early as possible.
While global literature monitoring remains a fundamental pharmacovigilance activity, local literature monitoring has become increasingly important, particularly in rapidly growing healthcare markets such as the United Arab Emirates (UAE) and the wider Gulf Cooperation Council (GCC).
As healthcare systems expand, local research output increases, and regulatory expectations mature, scientific publications originating within the region provide valuable real-world evidence that may never appear in international databases.
What Is Local Literature Monitoring?
Local literature monitoring is the systematic review of scientific publications from a specific country or region to identify potential safety information related to medicinal products.
These publications may include adverse drug reactions (ADRs), medication errors, lack of efficacy, drug interactions, off-label use, or safety concerns in special populations.
Unlike traditional global searches that rely primarily on databases such as PubMed or Embase, local monitoring focuses on national medical journals, university publications, hospital research, conference proceedings, and government publications.
In multilingual regions like the GCC, relevant evidence may also be published in Arabic, making local expertise particularly valuable.
Why Local Safety Evidence Matters
The importance of this process continues to grow as regulators recognize that medicine safety profiles are not always identical across different populations.
Factors such as genetics, disease prevalence, prescribing practices, environmental conditions, and healthcare infrastructure can all influence how medicines perform in real-world settings.
For example, the UAE has one of the highest diabetes prevalence rates globally, with approximately 20% of adults living with diabetes, according to the International Diabetes Federation.
As newer therapies such as GLP-1 receptor agonists become more widely used, locally published case reports describing unexpected adverse events may provide important safety insights before similar findings appear in international literature.
Growing Regulatory Expectations
Across the world, regulators increasingly expect pharmaceutical companies to include scientific literature as part of their pharmacovigilance systems.
The European Medicines Agency (EMA) considers medical literature an essential source of adverse reaction reports and has operated its centralized Medical Literature Monitoring (MLM) service since 2015.
Today, the service screens millions of MEDLINE citations each year to identify reportable safety cases and emerging signals.
Similarly, the UAE Emirates Drug Establishment requires Marketing Authorization Holders to maintain effective pharmacovigilance systems capable of identifying, collecting, evaluating, and reporting safety information throughout the lifecycle of their products.
Although global literature monitoring is well established, local publications remain an important source of safety information, particularly when evidence is generated within UAE healthcare institutions.
This growing regulatory focus reflects a broader recognition that many important safety signals first emerge in routine clinical practice rather than during controlled clinical trials.
Why the UAE and GCC Present Unique Pharmacovigilance Challenges
Healthcare across the GCC has expanded significantly over the past decade. Governments continue to invest heavily in hospitals, specialized treatment centres, medical universities, and clinical research, resulting in a steady increase in locally generated scientific publications.
Institutions such as Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City, King Faisal Specialist Hospital in Saudi Arabia, Hamad Medical Corporation in Qatar, and Sultan Qaboos University Hospital in Oman regularly publish clinical studies and case reports that contribute valuable regional safety evidence.
These publications often reflect healthcare practices that differ from those seen in Europe or North America.
The GCC has higher rates of diabetes, obesity, cardiovascular disease, and certain hereditary disorders, while prescribing habits, treatment guidelines, and patient demographics may vary considerably.
As a result, local literature can reveal adverse reactions or risk factors that are particularly relevant to patients within the region.
How Local Literature Can Reveal Emerging Safety Signals
Consider a scenario where physicians at a UAE hospital publish several case reports describing unexpected gastrointestinal complications associated with a newly introduced diabetes medicine.
If these reports appear only in a local journal, companies relying exclusively on international databases may fail to identify the signal until much later.
Early detection through local literature monitoring enables timely safety assessment, regulatory reporting, and appropriate risk management activities.
Similar examples exist in dermatology and aesthetics, two rapidly growing therapeutic areas in the UAE.
Local dermatologists frequently publish observations on allergic reactions, skin sensitivities, and product misuse associated with cosmetic procedures or dermatological products.
Such findings may represent important regional safety trends that would otherwise remain overlooked.
The Growing Volume of Medical Literature
The scale of medical literature continues to expand every year. MEDLINE alone contains more than 36 million biomedical citations, while thousands of new scientific articles are added every week.
Alongside this global growth, research output from GCC institutions has increased steadily, making regional literature monitoring more resource-intensive than ever before.
For pharmaceutical companies operating across multiple GCC markets, manually reviewing numerous journals, conference proceedings, and regional publications can quickly become a complex and time-consuming process.
Many local journals are not indexed in major international databases, and publications may appear in both English and Arabic, requiring specialized search strategies and experienced reviewers.
From Literature Identification to ICSR Assessment
Even after identifying a relevant publication, pharmacovigilance professionals must determine whether it qualifies as a valid Individual Case Safety Report (ICSR), assess causality, eliminate duplicates, and ensure timely reporting in accordance with local regulatory requirements.
Local literature monitoring should not be viewed simply as another regulatory obligation. When implemented effectively, it strengthens signal detection, supports benefit-risk assessments, and ultimately contributes to safer use of medicines.
Technology, AI, and the Importance of Local Expertise
As pharmacovigilance continues to embrace artificial intelligence, automated literature screening, and advanced signal detection technologies, local expertise remains essential.
Technology can accelerate searches, but interpreting medical evidence, assessing reportability, and understanding regional healthcare practices still require experienced pharmacovigilance professionals.
For companies operating in the UAE and GCC, combining global literature surveillance with robust local monitoring provides a more comprehensive understanding of product safety while helping meet the evolving expectations of regional health authorities.
Building a Strong Pharmacovigilance System in the GCC
Keeping pace with pharmacovigilance requirements across the UAE and GCC requires regional expertise, regulatory knowledge, and a structured quality system.
At PRA Consultancy, we help pharmaceutical, biotechnology, medical device, cosmetics, and healthcare companies establish compliant pharmacovigilance systems tailored to regional regulations.
Our services include:
-
Local Literature Monitoring
-
Individual Case Safety Report (ICSR) processing
-
Signal management
-
Risk Management Plans (RMPs)
-
PSUR/PBRER preparation
-
Pharmacovigilance System Master Files (PSMFs)
-
QPPV support
-
Pharmacovigilance audits
-
Regulatory consulting across the GCC